BioCentury | Mar 10, 2014
Company News

Olympus Corp. musculoskeletal news

...reasons. Olympus Biotech will discontinue its osteoinductive and osteoconductive bone graft materials OP-1 PUTTY and OPI-1...
BioCentury | Jan 27, 2014
Finance

Going big

...exits have included cancer play OPi S.A. and endoscopic tool manufacturer Mauna Kea Technologies S.A. (Euronext:MKEA). OPi...
BioCentury | Feb 25, 2013
Clinical News

OSE 2101 regulatory update

...TAA). OSE-Pharma has worldwide development rights and European commercialization rights to the cancer vaccine from EU Synergy Epitopes...
...16, 2012). The product has also completed a Phase I/II trial to treat colorectal cancer. EU Synergy Epitopes...
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...Emile Loria at Epimmune Inc. OSE-Pharma acquired worldwide development rights and European commercialization rights from EU Synergy Epitopes...
...Japan), which out-licensed EP2101 in 2011 to Biotech Synergy (San Diego, Calif.), which Loria founded. EU Synergy Epitopes...
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...EP2101 in 2011 to a new San Diego-based company founded by Loria, Biotech Synergy . EU Synergy Epitopes...
BioCentury | May 5, 2008
Company News

Alize Pharma, EUSA, International Drug Development Institute deal

...Financial terms were not disclosed. EUSA acquired both programs as part of its acquisition of OPi S.A....
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...& Co. KG (Marburg, Germany) holds marketing rights to Nitoman in Germany and Austria, and OPi S.A....
BioCentury | Sep 24, 2007
Company News

Alize Pharma board of directors update

...Alize Pharma S.A.S. , Lyon, France Business: Endocrine Appointed: Gilles Alberici, former president of OPi S.A. WIR Staff...
BioCentury | May 14, 2007
Finance

Ebb & Flow

...the $175 million that went to specialty pharma EUSA for the acquisition of oncology company OPi...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...EUSA : a $175 million B round to fund its acquisition of orphan drug specialist OPi...
Items per page:
1 - 10 of 21
BioCentury | Mar 10, 2014
Company News

Olympus Corp. musculoskeletal news

...reasons. Olympus Biotech will discontinue its osteoinductive and osteoconductive bone graft materials OP-1 PUTTY and OPI-1...
BioCentury | Jan 27, 2014
Finance

Going big

...exits have included cancer play OPi S.A. and endoscopic tool manufacturer Mauna Kea Technologies S.A. (Euronext:MKEA). OPi...
BioCentury | Feb 25, 2013
Clinical News

OSE 2101 regulatory update

...TAA). OSE-Pharma has worldwide development rights and European commercialization rights to the cancer vaccine from EU Synergy Epitopes...
...16, 2012). The product has also completed a Phase I/II trial to treat colorectal cancer. EU Synergy Epitopes...
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...Emile Loria at Epimmune Inc. OSE-Pharma acquired worldwide development rights and European commercialization rights from EU Synergy Epitopes...
...Japan), which out-licensed EP2101 in 2011 to Biotech Synergy (San Diego, Calif.), which Loria founded. EU Synergy Epitopes...
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...EP2101 in 2011 to a new San Diego-based company founded by Loria, Biotech Synergy . EU Synergy Epitopes...
BioCentury | May 5, 2008
Company News

Alize Pharma, EUSA, International Drug Development Institute deal

...Financial terms were not disclosed. EUSA acquired both programs as part of its acquisition of OPi S.A....
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...& Co. KG (Marburg, Germany) holds marketing rights to Nitoman in Germany and Austria, and OPi S.A....
BioCentury | Sep 24, 2007
Company News

Alize Pharma board of directors update

...Alize Pharma S.A.S. , Lyon, France Business: Endocrine Appointed: Gilles Alberici, former president of OPi S.A. WIR Staff...
BioCentury | May 14, 2007
Finance

Ebb & Flow

...the $175 million that went to specialty pharma EUSA for the acquisition of oncology company OPi...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...EUSA : a $175 million B round to fund its acquisition of orphan drug specialist OPi...
Items per page:
1 - 10 of 21